Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Modified-Release Drug Delivery Systems: Rate-Programmed II

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

Modified-Release Drug Delivery Systems: Bioavailability

Modified-Release Drug Delivery Systems: Bioavailability

Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...

Modified-Release Drug Delivery Systems: Rate-Programmed I

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...

Modified-Release Drug Delivery Systems: Stimuli-Activated

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Characteristic of a Biodegradable Foam With Bagasse as a Filler.

Scientifica·2026

Same author

Breakthroughs and Opportunities of Biopolymer Coatings: A Bibliometric Analysis on Their Future Prospects for the Sustainable Food Packaging Industry.

TheScientificWorldJournal·2025

Same author

Seasonal nutrient contribution of mangrove aquatic foods to fisher households in West Kalimantan, Indonesia.

BMC public health·2025

Same author

Effect of Cinnamaldehyde Addition on Injectable Gypsum-Calcium Carbonate Hydrogel Paste with Ultraviolet Light Polymerization: Bone Scaffold Material for Implant.

European journal of dentistry·2025

Same author

Reducing the Radioactive Surface Contamination Level of Cobalt-60-Contaminated Material with PVA-Glycerol-EDTA Combination Gel.

Gels (Basel, Switzerland)·2025

Same author

Comparative Analysis of Volatile Compounds and Biochemical Activity of <i>Curcuma xanthorrhiza</i> Roxb. Essential Oil Extracted from Distinct Shaded Plants.

Plants (Basel, Switzerland)·2024

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

Rifampicin adsorption and release study using Santa Barbara amorphous-16 modified Al (SBA-16-Al) for a drug delivery

Maria Christina Prihatiningsih¹, Chaidir Pratama², Noor Anis Kundari¹

¹Polytechnic Institute of Nuclear Technology, National Research and Innovation Agency (BRIN) Yogyakarta Indonesia maria.christina@polteknuklir.ac.id mari003@brin.go.id.

|March 4, 2024

Summary

Aluminum-modified Santa Barbara Amorphous-16 (SBA-16-Al) serves as an effective rifampicin matrix for tuberculosis treatment. This mesoporous material exhibits excellent adsorption and controlled release properties for enhanced drug delivery.

More Related Videos

Author Spotlight: Advancing Therapeutics with Biocompatible Sodium Alginate Hydrogel Microspheres

Author Spotlight: Advancing Therapeutics with Biocompatible Sodium Alginate Hydrogel Microspheres

Published on: June 7, 2024

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing

Published on: December 13, 2024

Related Experiment Videos

Last Updated: Jun 25, 2026

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

Author Spotlight: Advancing Therapeutics with Biocompatible Sodium Alginate Hydrogel Microspheres

Author Spotlight: Advancing Therapeutics with Biocompatible Sodium Alginate Hydrogel Microspheres

Published on: June 7, 2024

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing

Published on: December 13, 2024

Area of Science:

Materials Science
Nanotechnology
Pharmaceutical Sciences

Background:

Tuberculosis (TB) remains a significant global health challenge, necessitating advanced drug delivery systems.
Mesoporous silica materials offer promising platforms for drug encapsulation and controlled release.
Surface modification of these materials can enhance their therapeutic efficacy.

Purpose of the Study:

To develop and characterize an aluminum-modified SBA-16 (SBA-16-Al) matrix for rifampicin delivery.
To investigate the adsorption and release kinetics of rifampicin from the SBA-16-Al matrix.
To evaluate the potential of SBA-16-Al as a drug carrier for tuberculosis treatment.

Main Methods:

Surface modification of SBA-16 using a direct-synthesis grafting method.
Characterization of SBA-16-Al using FTIR, XRD, TEM, and BET surface area analysis.
Batch studies to determine rifampicin adsorption isotherms and release kinetics.

Main Results:

SBA-16-Al exhibited a high surface area (843.5 m²/g) and nanometer-sized pores.
FTIR confirmed successful aluminum incorporation into the SBA-16 structure (Al-O bond at 802 cm⁻¹).
Rifampicin adsorption followed the Freundlich model (heterogeneous, multilayer adsorption) and was identified as stable chemisorption.
Rifampicin release kinetics adhered to the Higuchi model at different pH values.

Conclusions:

SBA-16-Al is a suitable matrix for rifampicin, demonstrating effective adsorption and controlled release.
The material's properties suggest potential for developing improved tuberculosis drug delivery systems.
Further in vivo studies are warranted to confirm therapeutic efficacy.